JP2017039714A - ヒドロキシトリアジン化合物及びその医薬用途 - Google Patents

ヒドロキシトリアジン化合物及びその医薬用途 Download PDF

Info

Publication number
JP2017039714A
JP2017039714A JP2016159454A JP2016159454A JP2017039714A JP 2017039714 A JP2017039714 A JP 2017039714A JP 2016159454 A JP2016159454 A JP 2016159454A JP 2016159454 A JP2016159454 A JP 2016159454A JP 2017039714 A JP2017039714 A JP 2017039714A
Authority
JP
Japan
Prior art keywords
compound
pharmaceutically acceptable
acid
acceptable salt
added
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2016159454A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017039714A5 (enExample
Inventor
育生 三谷
Ikuo Mitani
育生 三谷
佑太郎 廣野
Yutaro Hirono
佑太郎 廣野
山下　正樹
Masaki Yamashita
正樹 山下
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Japan Tobacco Inc
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of JP2017039714A publication Critical patent/JP2017039714A/ja
Publication of JP2017039714A5 publication Critical patent/JP2017039714A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/22—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to two ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2016159454A 2015-08-17 2016-08-16 ヒドロキシトリアジン化合物及びその医薬用途 Ceased JP2017039714A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015160284 2015-08-17
JP2015160284 2015-08-17

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020148973A Division JP2020193235A (ja) 2015-08-17 2020-09-04 ヒドロキシトリアジン化合物及びその医薬用途

Publications (2)

Publication Number Publication Date
JP2017039714A true JP2017039714A (ja) 2017-02-23
JP2017039714A5 JP2017039714A5 (enExample) 2019-09-19

Family

ID=58052084

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016159454A Ceased JP2017039714A (ja) 2015-08-17 2016-08-16 ヒドロキシトリアジン化合物及びその医薬用途
JP2020148973A Ceased JP2020193235A (ja) 2015-08-17 2020-09-04 ヒドロキシトリアジン化合物及びその医薬用途
JP2022128590A Pending JP2022163169A (ja) 2015-08-17 2022-08-12 ヒドロキシトリアジン化合物及びその医薬用途
JP2023207429A Active JP7640658B2 (ja) 2015-08-17 2023-12-08 ヒドロキシトリアジン化合物及びその医薬用途

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2020148973A Ceased JP2020193235A (ja) 2015-08-17 2020-09-04 ヒドロキシトリアジン化合物及びその医薬用途
JP2022128590A Pending JP2022163169A (ja) 2015-08-17 2022-08-12 ヒドロキシトリアジン化合物及びその医薬用途
JP2023207429A Active JP7640658B2 (ja) 2015-08-17 2023-12-08 ヒドロキシトリアジン化合物及びその医薬用途

Country Status (19)

Country Link
US (3) US20170057943A1 (enExample)
EP (2) EP4046991A1 (enExample)
JP (4) JP2017039714A (enExample)
KR (1) KR20180037270A (enExample)
CN (1) CN108137515B (enExample)
AR (1) AR105711A1 (enExample)
AU (1) AU2016309337B2 (enExample)
BR (1) BR112018001809A2 (enExample)
CA (1) CA2992410A1 (enExample)
CL (1) CL2018000430A1 (enExample)
CO (1) CO2018002516A2 (enExample)
IL (1) IL257559B (enExample)
MX (1) MX375283B (enExample)
PE (1) PE20180951A1 (enExample)
PH (1) PH12018500181A1 (enExample)
SG (1) SG11201800698VA (enExample)
TW (1) TWI704139B (enExample)
WO (1) WO2017030115A1 (enExample)
ZA (1) ZA201801134B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022163169A (ja) * 2015-08-17 2022-10-25 日本たばこ産業株式会社 ヒドロキシトリアジン化合物及びその医薬用途

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI651310B (zh) 2014-02-20 2019-02-21 日商日本煙草產業股份有限公司 三化合物及其醫藥用途
US10710967B2 (en) * 2015-10-29 2020-07-14 Aska Pharmaceutical Co., Ltd. Pyrimidine derivative
RU2648181C1 (ru) * 2017-05-25 2018-03-22 Федеральное государственное автономное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации Способ лечения нейроретинопатии вследствие тяжелой преэклампсии
CN110799506B (zh) * 2017-06-26 2024-03-01 默克专利有限公司 用于制备被取代的含氮杂环化合物的方法
KR20250030486A (ko) * 2022-07-06 2025-03-05 아스카 세이야쿠 가부시키가이샤 피리미딘 유도체

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010037059A2 (en) * 2008-09-29 2010-04-01 Amira Pharmaceuticals, Inc. Heteroaryl antagonists of prostaglandin d2 receptors
WO2011037610A1 (en) * 2009-09-23 2011-03-31 Albert Einstein College Of Medicine Of Yeshiva University Prostaglandin transporter inhibitors and uses thereof
JP2011525905A (ja) * 2008-06-26 2011-09-29 田辺三菱製薬株式会社 神経変性疾患治療用のｇｓｋ３−ベータ阻害剤としての４−（ピリジン−４−イル）−１ｈ−（１，３，５）トリアジン−２−オン誘導体
JP2012511517A (ja) * 2008-12-10 2012-05-24 上海特化医薬科技有限公司 フェニルピリミドン骨格を有する化合物、その薬剤組成物、その製造方法及び用途
JP2014518886A (ja) * 2011-05-26 2014-08-07 イーライ リリー アンド カンパニー 関節炎の治療に有用な新規イミダゾール誘導体
WO2015059618A1 (en) * 2013-10-22 2015-04-30 Glenmark Pharmaceuticals S.A. SUBSTITUTED PYRIMIDINE COMPOUNDS AS mPGES-1 INHIBITORS
JP2015523353A (ja) * 2012-06-15 2015-08-13 グレンマーク・ファーマシューティカルズ・エスエー ｍＰＧＥＳ−１阻害剤としてのトリアゾロン化合物
JP6461637B2 (ja) * 2014-02-20 2019-01-30 日本たばこ産業株式会社 トリアジン化合物及びその医薬用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH473818A (de) 1964-03-18 1969-06-15 Ciba Geigy Verfahren zur Herstellung von neuen Hydroxyphenyl-1,3,5-triazinen und deren Verwendung
SU1313854A1 (ru) 1985-04-17 1987-05-30 Институт Органической Химии Ан Армсср Способ получени смеси 2-оксо-2,3-дигидро-4,6,-бис-(3 @ -диэтиламинометилен-4 @ -оксифенил)-1,3,5-триазина и 2,4,6-трис-(3 @ -диэтиламинометилен-4 @ -оксифенил)-1,3,5-триазина
DE19543730A1 (de) 1995-11-23 1997-05-28 Ciba Geigy Ag Bis-Resorcinyl-Triazine
US6096753A (en) 1996-12-05 2000-08-01 Amgen Inc. Substituted pyrimidinone and pyridone compounds and methods of use
US6410729B1 (en) 1996-12-05 2002-06-25 Amgen Inc. Substituted pyrimidine compounds and methods of use
ZA9710727B (en) 1996-12-05 1998-06-12 Amgen Inc Substituted pyrimidine compounds and methods of use.
WO1998024782A2 (en) 1996-12-05 1998-06-11 Amgen Inc. Substituted pyrimidine compounds and their use
GB9726987D0 (en) 1997-12-22 1998-02-18 Glaxo Group Ltd Compounds
EA004656B1 (ru) 1999-04-01 2004-06-24 Пфайзер Продактс Инк. Аминопиримидины в качестве ингибиторов сорбитолдегидрогеназы
ES2398854T3 (es) 2007-04-03 2013-03-22 E. I. Du Pont De Nemours And Company Fungicidas de benceno sustituido
JP5388270B2 (ja) 2008-06-04 2014-01-15 株式会社Ａｄｅｋａ ２，４，６−トリス（ヒドロキシフェニル）−１，３，５−トリアジン化合物の製造方法
US8716474B2 (en) 2008-06-04 2014-05-06 Adeka Corporation Method for producing 2,4,6-tris(hydroxyphenyl)-1,3,5-triazine compound
AR077999A1 (es) 2009-09-02 2011-10-05 Vifor Int Ag Antagonistas de pirimidin y triazin-hepcidina
WO2011048004A1 (en) 2009-10-23 2011-04-28 Boehringer Ingelheim International Gmbh Inhibitors of the microsomal prostaglandin e2 synthase-1
US8586604B2 (en) 2010-08-20 2013-11-19 Boehringer Ingelheim International Gmbh Inhibitors of the microsomal prostaglandin E2 synthase-1
FR2983859B1 (fr) 2011-12-12 2014-01-17 Sanofi Sa Derives de 1,3,5-triazine-2-amine, leur preparation et leur application en diagnostique et en therapeutique
CA2873984A1 (en) 2012-05-23 2013-11-28 Stemergie Biotechnology Sa Inhibitors of the activity of complex (iii) of the mitochondrial electron transport chain and use thereof
CN105586773A (zh) 2014-11-13 2016-05-18 东丽纤维研究所（中国）有限公司 一种拒水抗紫外纺织品及其生产方法和用途
JP2017039714A (ja) * 2015-08-17 2017-02-23 日本たばこ産業株式会社 ヒドロキシトリアジン化合物及びその医薬用途

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011525905A (ja) * 2008-06-26 2011-09-29 田辺三菱製薬株式会社 神経変性疾患治療用のｇｓｋ３−ベータ阻害剤としての４−（ピリジン−４−イル）−１ｈ−（１，３，５）トリアジン−２−オン誘導体
WO2010037059A2 (en) * 2008-09-29 2010-04-01 Amira Pharmaceuticals, Inc. Heteroaryl antagonists of prostaglandin d2 receptors
JP2012511517A (ja) * 2008-12-10 2012-05-24 上海特化医薬科技有限公司 フェニルピリミドン骨格を有する化合物、その薬剤組成物、その製造方法及び用途
WO2011037610A1 (en) * 2009-09-23 2011-03-31 Albert Einstein College Of Medicine Of Yeshiva University Prostaglandin transporter inhibitors and uses thereof
JP2014518886A (ja) * 2011-05-26 2014-08-07 イーライ リリー アンド カンパニー 関節炎の治療に有用な新規イミダゾール誘導体
JP2015523353A (ja) * 2012-06-15 2015-08-13 グレンマーク・ファーマシューティカルズ・エスエー ｍＰＧＥＳ−１阻害剤としてのトリアゾロン化合物
WO2015059618A1 (en) * 2013-10-22 2015-04-30 Glenmark Pharmaceuticals S.A. SUBSTITUTED PYRIMIDINE COMPOUNDS AS mPGES-1 INHIBITORS
JP6461637B2 (ja) * 2014-02-20 2019-01-30 日本たばこ産業株式会社 トリアジン化合物及びその医薬用途

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022163169A (ja) * 2015-08-17 2022-10-25 日本たばこ産業株式会社 ヒドロキシトリアジン化合物及びその医薬用途

Also Published As

Publication number Publication date
BR112018001809A2 (pt) 2018-09-18
CN108137515B (zh) 2021-07-06
JP7640658B2 (ja) 2025-03-05
US12492182B2 (en) 2025-12-09
TW201718524A (zh) 2017-06-01
SG11201800698VA (en) 2018-03-28
AU2016309337B2 (en) 2021-03-04
KR20180037270A (ko) 2018-04-11
RU2018109220A (ru) 2019-09-19
JP2020193235A (ja) 2020-12-03
CO2018002516A2 (es) 2018-05-31
IL257559A (en) 2018-04-30
IL257559B (en) 2021-07-29
EP3339296A1 (en) 2018-06-27
JP2024019449A (ja) 2024-02-09
CL2018000430A1 (es) 2018-08-03
MX2018002044A (es) 2018-04-13
US20210024486A1 (en) 2021-01-28
CN108137515A (zh) 2018-06-08
EP4046991A1 (en) 2022-08-24
WO2017030115A1 (ja) 2017-02-23
RU2018109220A3 (enExample) 2019-11-15
US20240076278A1 (en) 2024-03-07
US20170057943A1 (en) 2017-03-02
PH12018500181A1 (en) 2018-07-30
AR105711A1 (es) 2017-11-01
ZA201801134B (en) 2019-07-31
CA2992410A1 (en) 2017-02-23
TWI704139B (zh) 2020-09-11
AU2016309337A1 (en) 2018-02-01
MX375283B (es) 2025-03-06
JP2022163169A (ja) 2022-10-25
EP3339296A4 (en) 2019-01-23
PE20180951A1 (es) 2018-06-11

Similar Documents

Publication Publication Date Title
JP2022120173A (ja) トリアジン化合物及びその医薬用途
JP7640658B2 (ja) ヒドロキシトリアジン化合物及びその医薬用途
CN102149384B (zh) 作为ep4受体拮抗剂的杂环酰胺衍生物
JP2020533337A (ja) 重水素原子置換インドールホルムアミド誘導体、その調製方法、およびその医療用途
RU2772907C2 (ru) Соединение гидрокситриазина и его применение в медицинских целях
HK40079824A (en) Hydroxytriazine compounds and pharmaceutical use thereof
HK1256768A1 (en) Hydroxytriazine compound and medical use thereof
WO2022037601A1 (zh) 作为ep4受体拮抗剂的吡唑酰胺衍生物及其在制备治疗癌症和炎症药物中的用途
WO2006090850A1 (ja) ベンズアミド化合物
NZ721718B2 (en) Triazine compound and use thereof for medical purposes

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190809

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190809

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200611

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200707

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200729

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20201124